Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Nervous System Diseases

Behaviors and Mental Disorders

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Alzheimer Disease

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery

Pathologic N2 NSCLC patients who received lobectomy by thoracotomy

Patients who received lobectomy by video-assisted thoracoscopic surgery

VATS lobectomy

Patients who received lobectomy by thoracotomy

Thoracotomy lobectomy

Xiaofei Li, PhD

The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer

The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on patient demographic, clinical characteristics, treatment and clinical outcomes will be collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy for pathologic N2 NSCLC.

Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients

Vedio-assisted Thoracoscopic Lobectomy vs Open Lobectomy for Patients With Surgically Resectable Pathologic N2 NSCLC

Overall survivals in the subgroups stratified by T staging

Overall survivals in the subgroups stratified by neoadjuvant therapy

Overall survivals in the subgroups stratified by number of lymph node station involved

Impact factors for postoperative mortality within 30/90 days

Propensity score matching analysis of overall survival

Propensity score matching analysis of perioperative outcomes

Propensity score matching analysis of impact factors for overall survival

Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days

Duration of hospital stay \[Perioperative outcomes\]

Postoperative 30 and 90 days \[Perioperative outcomes\]

Intraoperative blood loss \[Perioperative outcomes\]

Postoperative complications \[Perioperative outcomes\]

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients	NCT03613467	Non-small Cell ...	VATS lobectomy Thoracotomy lob...	18 Years -	Tang-Du Hospital
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients	NCT03613467	Non-small Cell ...	VATS lobectomy Thoracotomy lob...	18 Years -	Tang-Du Hospital
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients	NCT03613467	Non-small Cell ...	VATS lobectomy Thoracotomy lob...	18 Years -	Tang-Du Hospital

Spots Global Cancer Trial Database for thoracotomy lobectomy